Publications by authors named "Keri Stenger"
Article Synopsis
- This study evaluated the effectiveness and patterns of use for biologic and targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs) in treating psoriatic arthritis (PsA) among patients from 2015 to 2019, including adherence, persistence, and healthcare costs.
- A total of 6,674 adult PsA patients were analyzed, with the most commonly used treatments being adalimumab (37%), apremilast (26%), and etanercept (18%).
- Findings will help understand the real-world application of these therapies, highlighting variations in patient treatment adherence and related healthcare expenditures over a 12-month follow-up.
Purpose: To describe patients' perspectives on the use of and potential challenges and barriers with adherence/persistence to cyclin-dependent kinase 4 and 6 inhibitors (CDK4&6i's) to treat metastatic breast cancer (MBC).
Methods: This qualitative study consisted of 60-minute semi-structured telephone interviews with patients with MBC in the US who were either current or recent CDK4&6i users, identified from administrative claims of survey-eligible commercial and Medicare Advantage patients in the HealthCore Integrated Research Database between November 1, 2018 and November 1, 2019. Patients were recruited by email and/or mailed letter.
Article Synopsis
- The objective of the study was to evaluate how well patients with psoriatic arthritis (PsA) adhere to, persist with, or discontinue treatment using ixekizumab (IXE), as well as analyze related health care costs.
- The study tracked 496 adults who began IXE treatment between January 2016 and June 2019, finding that 52.8% maintained persistent use, while 38.7% discontinued, and 70.6% were highly adherent.
- IXE accounted for a significant portion of PsA-related health care costs, averaging $5,233 per month, but patient out-of-pocket expenses were low, and adjusting for discounts reduced overall costs by $2,509 per
Purpose: Advanced breast cancer is a heterogeneous disease with several well-defined subtypes, among which, hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) is most prevalent. Determination of HR and HER2 status influences prognosis and, thus, disease management. Although literature on these prognostic factors exist, especially in the early breast cancer setting, it remains unclear to what extent these factors can guide clinical decision-making in the advanced disease setting.
View Article and Find Full Text PDF